 | N2 - Most kids with acute immune thrombocytopenic purpura (ITP) reply to first-line therapies together with intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. Nonetheless, there is no such thing as a clear consensus relating to second-line therapies for the remedy of ITP, not responding to first-line therapies within the acute setting. Adapting from the chronic ITP literature, three patients with acute refractory ITP had been handled with intravenous rituximab and confirmed rapid and sustained remission. Mixed therapy that features rituximab could also be an efficient regimen for acute refractory ITP. AB - Most youngsters with acute immune thrombocytopenic purpura (ITP) reply to first-line therapies together with intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. Nevertheless, there isn't any clear consensus relating to second-line therapies for the remedy of ITP, not responding to first-line therapies within the acute setting. Adapting from the chronic ITP literature, three patients with acute refractory ITP have been handled with intravenous rituximab and confirmed quick and sustained remission. Mixed therapy that features rituximab could also be an efficient regimen for acute refractory ITP. |
[返信]